Literature DB >> 25546744

Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies.

M Seppänen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546744      PMCID： PMC4285473          DOI： 10.1111/cei.12493

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  32 in total

1.  Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors.

Authors:  H Griffiths; V Brennan; J Lea; C Bunch; M Lee; H Chapel
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

2.  Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma.

Authors:  P Musto; M Brugiatelli; M Carotenuto
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

3.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

Authors:  Aaron P Rapoport; Edward A Stadtmauer; Nicole Aqui; Ashraf Badros; Julio Cotte; Lisa Chrisley; Elizabeth Veloso; Zhaohui Zheng; Sandra Westphal; Rebecca Mair; Nina Chi; Bashi Ratterree; Mary Francis Pochran; Sabrina Natt; Joanne Hinkle; Cheryl Sickles; Ambika Sohal; Kathleen Ruehle; Christian Lynch; Lei Zhang; David L Porter; Selina Luger; Chuanfa Guo; Hong-Bin Fang; William Blackwelder; Kim Hankey; Dean Mann; Robert Edelman; Carl Frasch; Bruce L Levine; Alan Cross; Carl H June
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

Review 4.  Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.

Authors:  Sercan Aksoy; Omer Dizdar; Mutlu Hayran; Hakan Harputluoğlu
Journal:  Leuk Lymphoma       Date:  2009-03

5.  Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.

Authors:  L Baldini; A Guffanti; B M Cesana; M Colombi; O Chiorboli; I Damilano; A T Maiolo
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

6.  Immunological factors and risk of infection in plateau phase myeloma.

Authors:  R M Hargreaves; J R Lea; H Griffiths; J A Faux; J M Holt; C Reid; C Bunch; M Lee; H M Chapel
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

7.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes.

Authors:  Helen Chapel; Mary Lucas; Martin Lee; Janne Bjorkander; David Webster; Bodo Grimbacher; Claire Fieschi; Vojtech Thon; Mohammad R Abedi; Lennart Hammarstrom
Journal:  Blood       Date:  2008-03-04       Impact factor: 22.113

Review 8.  The immunodeficiency of chronic lymphocytic leukaemia.

Authors:  A D Hamblin; T J Hamblin
Journal:  Br Med Bull       Date:  2008-08-27       Impact factor: 4.291

Review 9.  Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis.

Authors:  Pia Raanani; Anat Gafter-Gvili; Mical Paul; Isaac Ben-Bassat; Leonard Leibovici; Ofer Shpilberg
Journal:  Leuk Lymphoma       Date:  2009-05

10.  Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma.

Authors:  H M Chapel; M Lee; R Hargreaves; D H Pamphilon; A G Prentice
Journal:  Lancet       Date:  1994-04-30       Impact factor: 79.321
View more
  2 in total

Review 1.  The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Authors:  Smita Y Patel; Javier Carbone; Stephen Jolles
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

2.  Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics.

Authors:  Idanna Innocenti; Annamaria Tomasso; Giulia Benintende; Francesco Autore; Alberto Fresa; Florenzia Vuono; Luca Stirparo; Eugenio Galli; Giovanni D'Arena; Federica Sorà; Dimitar Efremov; Luca Laurenti
Journal:  Hematol Oncol       Date:  2022-02-02       Impact factor: 4.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.